The current stock price of ISRG is 586.24 USD. In the past month the price increased by 5.45%. In the past year, price increased by 7.08%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B | ||
| HOLX | HOLOGIC INC | 17.53 | 16.69B |
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
INTUITIVE SURGICAL INC
1020 Kifer Road
Sunnyvale CALIFORNIA 94086 US
CEO: Gary S. Guthart
Employees: 15638
Phone: 14085232100
Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. The company is headquartered in Sunnyvale, California and currently employs 15,638 full-time employees. The company went IPO on 2000-06-13. The firm specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
The current stock price of ISRG is 586.24 USD. The price increased by 0.2% in the last trading session.
ISRG does not pay a dividend.
ISRG has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
ISRG stock is listed on the Nasdaq exchange.
INTUITIVE SURGICAL INC (ISRG) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
INTUITIVE SURGICAL INC (ISRG) has a market capitalization of 207.82B USD. This makes ISRG a Mega Cap stock.
ChartMill assigns a technical rating of 9 / 10 to ISRG. When comparing the yearly performance of all stocks, ISRG is one of the better performing stocks in the market, outperforming 80.86% of all stocks.
ChartMill assigns a fundamental rating of 7 / 10 to ISRG. ISRG scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months ISRG reported a non-GAAP Earnings per Share(EPS) of 8.61. The EPS increased by 28.12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.58% | ||
| ROA | 14.19% | ||
| ROE | 16.12% | ||
| Debt/Equity | 0 |
40 analysts have analysed ISRG and the average price target is 616.63 USD. This implies a price increase of 5.18% is expected in the next year compared to the current price of 586.24.
For the next year, analysts expect an EPS growth of 20.12% and a revenue growth 21.32% for ISRG